Skip to main content
Top
Published in: Cardiovascular Drugs and Therapy 6/2009

01-12-2009

Systolic Blood Pressure at Admission as a Predictor of the Response to Initial Carperitide Therapy in Patients Hospitalized for Acute Decompensated Heart Failure with Left Ventricular Systolic Dysfunction

Authors: Katsuya Kajimoto, Yukiko Sashida, Yuichiro Minami, Dai Yumino, Hirotaka Kawarai, Hiroshi Kasanuki

Published in: Cardiovascular Drugs and Therapy | Issue 6/2009

Login to get access

Abstract

Purpose

In patients with acute decompensated heart failure (ADHF) and left ventricular systolic dysfunction (LVSD), the role of initial vasodilator therapy remains uncertain. The present study aimed to evaluate the acute efficacy of initial carperitide therapy and to predict its response in ADHF patients with LVSD.

Methods

Twenty-four consecutive patients with ADHF and LVSD were enrolled. Inclusion criteria were a left ventricular ejection fraction < 40%, systolic blood pressure (BP) > 90 mm Hg, and pulmonary capillary wedge pressure ≥18 mm Hg at baseline. Hemodynamic parameters were evaluated by right heart catheterization before and after carperitide infusion. Responders were defined as a ≥30% reduction of pulmonary capillary wedge pressure (PCWP) or a decrease to < 16 mm Hg within 6 h after carperitide infusion.

Results

Seventeen (71%) of the 24 patients were responders for initial carperitide therapy. The responders had significantly higher systolic BP and cardiac index at baseline compared with nonresponders. The area under the curve (AUC) for systolic BP was 0.93 and a cut-off value of 120 mm Hg had a sensitivity of 94% and specificity of 86% for predicting the efficacy of carperitide. The AUC for the cardiac index was 0.88 and a cut-off value of 2.30 L/min/m2 had a sensitivity of 65% and a specificity of 100% for predicting the response to carperitide.

Conclusions

The initial use of carperitide therapy safely reduces PCWP in ADHF patients with LVSD and baseline systolic BP may be useful for predicting the response to initial carperitide therapy for ADHF with LVSD.
Literature
1.
go back to reference Gheorghiade M, Zannad F, Sopko G, International Working Group on Acute Heart Failure Syndromes, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958–68.CrossRefPubMed Gheorghiade M, Zannad F, Sopko G, International Working Group on Acute Heart Failure Syndromes, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958–68.CrossRefPubMed
2.
go back to reference De Luca L, Mebazaa A, Filippatos G, et al. Overview of emerging pharmacological agents for acute heart failure syndromes. Eur J Heart Fail. 2008;10:201–13.CrossRefPubMed De Luca L, Mebazaa A, Filippatos G, et al. Overview of emerging pharmacological agents for acute heart failure syndromes. Eur J Heart Fail. 2008;10:201–13.CrossRefPubMed
3.
go back to reference Nieminen MS, Harjola VP. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol. 2005;96:5G–10G.CrossRefPubMed Nieminen MS, Harjola VP. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol. 2005;96:5G–10G.CrossRefPubMed
4.
go back to reference Mebazaa A, Gheorghiade M, Piña IL, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008;36:S129–S39.CrossRefPubMed Mebazaa A, Gheorghiade M, Piña IL, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008;36:S129–S39.CrossRefPubMed
5.
go back to reference Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96:11G–7G.CrossRefPubMed Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96:11G–7G.CrossRefPubMed
6.
go back to reference Metra M, Teerlink JR, Voors AA, et al. Vasodilators in the treatment of acute heart failure: what we know, what we don’t. Heart Fail Rev 2008. Published online ahead of print 19 December 2008 Metra M, Teerlink JR, Voors AA, et al. Vasodilators in the treatment of acute heart failure: what we know, what we don’t. Heart Fail Rev 2008. Published online ahead of print 19 December 2008
7.
go back to reference Lee CYW, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007;12:131–42.CrossRefPubMed Lee CYW, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007;12:131–42.CrossRefPubMed
8.
go back to reference Saito Y, Nakao K, Nishimura K, et al. Clinical application of atrial polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation. 1987;76:115–24.PubMed Saito Y, Nakao K, Nishimura K, et al. Clinical application of atrial polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation. 1987;76:115–24.PubMed
9.
go back to reference Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Eng J Med. 2000;343:246–53.CrossRef Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Eng J Med. 2000;343:246–53.CrossRef
10.
go back to reference Publication Committee for the VMAC (Vasodilation in the management of acute CHF) Investigators. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–40.CrossRef Publication Committee for the VMAC (Vasodilation in the management of acute CHF) Investigators. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–40.CrossRef
11.
go back to reference Elkayam U, Akhter MW, Singh H, Khan S, Usman A. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol. 2004;93:237–40.CrossRefPubMed Elkayam U, Akhter MW, Singh H, Khan S, Usman A. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol. 2004;93:237–40.CrossRefPubMed
12.
go back to reference Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the ‘real world’ of therapy. Circ J. 2005;69:283–90.CrossRefPubMed Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the ‘real world’ of therapy. Circ J. 2005;69:283–90.CrossRefPubMed
13.
go back to reference Nomura F, Kurobe N, Mori Y, et al. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure-COMPASS: Carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study. Circ J. 2008;72:1777–86.CrossRefPubMed Nomura F, Kurobe N, Mori Y, et al. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure-COMPASS: Carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study. Circ J. 2008;72:1777–86.CrossRefPubMed
14.
go back to reference Nieminen MS, Böhm M, Cowie MR, et al. ESC Committe for Practice Guideline. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384–416.CrossRefPubMed Nieminen MS, Böhm M, Cowie MR, et al. ESC Committe for Practice Guideline. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384–416.CrossRefPubMed
15.
go back to reference Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:10–38.CrossRef Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:10–38.CrossRef
16.
go back to reference Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail. 2008;10:933–89.CrossRefPubMed Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail. 2008;10:933–89.CrossRefPubMed
17.
go back to reference Sackner-Bernstein JD, Skopicke HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–91.CrossRefPubMed Sackner-Bernstein JD, Skopicke HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–91.CrossRefPubMed
18.
go back to reference Sackner-Bernstein JD, Kawalski M, Fox M, Aaronson KD. Short-term risk of death after treatment with nesiritide for decompensated heart failure. JAMA. 2005;293:1900–5.CrossRefPubMed Sackner-Bernstein JD, Kawalski M, Fox M, Aaronson KD. Short-term risk of death after treatment with nesiritide for decompensated heart failure. JAMA. 2005;293:1900–5.CrossRefPubMed
19.
go back to reference Drazner MH, Hamilton MA, Fonarow G, Creaser J, Flavell C, Stevenson LW. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant. 1999;18:1126–32.CrossRefPubMed Drazner MH, Hamilton MA, Fonarow G, Creaser J, Flavell C, Stevenson LW. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant. 1999;18:1126–32.CrossRefPubMed
20.
go back to reference Larsen AI, Gøransson L, Aarsland T, Tamby JF, Dickstein K. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J. 1997;134:435–41.CrossRefPubMed Larsen AI, Gøransson L, Aarsland T, Tamby JF, Dickstein K. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J. 1997;134:435–41.CrossRefPubMed
21.
go back to reference Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction. J Am Coll Cardiol. 2007;50:1835–40.CrossRefPubMed Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction. J Am Coll Cardiol. 2007;50:1835–40.CrossRefPubMed
22.
go back to reference Serizawa T, Hirata Y, Kohmoto O, et al. Acute hemodynamic effects of alpha human atrial natriuretic polypeptide in patients with congestive heart failure. Jpn Heart J. 1988;29:143–9.PubMed Serizawa T, Hirata Y, Kohmoto O, et al. Acute hemodynamic effects of alpha human atrial natriuretic polypeptide in patients with congestive heart failure. Jpn Heart J. 1988;29:143–9.PubMed
23.
go back to reference Mizuno O, Onishi K, Dohi K, et al. Effects of therapeutic doses of human atrial natriuretic peptide on load and myocardial performance in patients with congestive heart failure. Am J Cardiol. 2001;88:863–6.CrossRefPubMed Mizuno O, Onishi K, Dohi K, et al. Effects of therapeutic doses of human atrial natriuretic peptide on load and myocardial performance in patients with congestive heart failure. Am J Cardiol. 2001;88:863–6.CrossRefPubMed
24.
go back to reference Cotter G, Williams SG, Vered Z, Tan LB. Role of cardiac power in heart failure. Curr Opin Cardiol. 2003;18:215–22.CrossRefPubMed Cotter G, Williams SG, Vered Z, Tan LB. Role of cardiac power in heart failure. Curr Opin Cardiol. 2003;18:215–22.CrossRefPubMed
25.
go back to reference Gheorghiade M, Abraham WT, Albert NM, et al. OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296:2217–26.CrossRefPubMed Gheorghiade M, Abraham WT, Albert NM, et al. OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296:2217–26.CrossRefPubMed
26.
go back to reference Milo-Cotter O, Adams KF, O’Connor CM, et al. Acute heart failure associated with high admission blood pressure: a distinct vascular disorder? Eur J Heart Fail. 2007;9:178–83.CrossRefPubMed Milo-Cotter O, Adams KF, O’Connor CM, et al. Acute heart failure associated with high admission blood pressure: a distinct vascular disorder? Eur J Heart Fail. 2007;9:178–83.CrossRefPubMed
27.
go back to reference Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402–12.CrossRefPubMed Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402–12.CrossRefPubMed
28.
go back to reference Florkowski CM, Richards AM, Espiner EA, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal men. Am J Physiol. 1994;266:R1244–50.PubMed Florkowski CM, Richards AM, Espiner EA, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal men. Am J Physiol. 1994;266:R1244–50.PubMed
29.
go back to reference Hunt PJ, Espiner EA, Richards AM, Yandle TG, Frampton C, Nicholls MG. Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men. Am J Physiol. 1995;269:R1397–R403.PubMed Hunt PJ, Espiner EA, Richards AM, Yandle TG, Frampton C, Nicholls MG. Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men. Am J Physiol. 1995;269:R1397–R403.PubMed
30.
go back to reference Kimura K, Yamaguchi Y, Horii M, et al. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol. 2007;63:699–702.CrossRefPubMed Kimura K, Yamaguchi Y, Horii M, et al. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol. 2007;63:699–702.CrossRefPubMed
Metadata
Title
Systolic Blood Pressure at Admission as a Predictor of the Response to Initial Carperitide Therapy in Patients Hospitalized for Acute Decompensated Heart Failure with Left Ventricular Systolic Dysfunction
Authors
Katsuya Kajimoto
Yukiko Sashida
Yuichiro Minami
Dai Yumino
Hirotaka Kawarai
Hiroshi Kasanuki
Publication date
01-12-2009
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 6/2009
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-009-6207-2

Other articles of this Issue 6/2009

Cardiovascular Drugs and Therapy 6/2009 Go to the issue